GOP-led Congress rejects Trump’s plans to gut medical research Senate bill gives NIH a $400 million raise

Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”

“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. https://open.spotify.com/episode/2PFYGwliBDYEbxBXFd9MtB?si=95DNBAy0QGSKBX31_uETEA This episode is available on Spotify, Apple Podcasts, and Youtube. Letai recapped his first year as NCI director in conversation with Paul Goldberg,...

October 07, 2026

Cancer Policy

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

NIH has introduced Linked Discoveries, an experimental tool designed to help scientists more easily see how an individual research finding relates to the larger body of biomedical evidence.

October 02, 2026

Vol.52 No.36

News Analysis

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

The White House last week considered, but ultimately abandoned, a plan to create a panel that would review NIH grants in an effort to weed out projects the administration regards as “woke.”

HHS issues direct final rule to reduce reliance on animal testing

FDA has issued a direct final rule that changes the language in its regulations so that “animal testing” is no longer described as the default or defining form of “nonclinical” safety testing.

September 25, 2026

Vol.52 No.35

By Claire Marie Porter

Funding Opportunities

Cancer Grand Challenges, through the Torrey Coast Foundation and Cancer Research UK, commits up to $34M to gastroesophageal cancer research

Cancer Grand Challenges has launched two new targeted challenges focused on gastroesophageal cancer, with awards of up to $34 million available through support from the Torrey Coast Foundation and Cancer Research UK.

September 25, 2026

Vol.52 No.35

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.

September 18, 2026

Vol.52 No.34

By Jeff Sorenson

GOP-led Congress rejects Trump’s plans to gut medical research

Senate bill gives NIH a $400 million raise

YOU MAY BE INTERESTED IN

Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

HHS issues direct final rule to reduce reliance on animal testing

Cancer Grand Challenges, through the Torrey Coast Foundation and Cancer Research UK, commits up to $34M to gastroesophageal cancer research

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Renew today!

Subscriber content

Never miss an issue!

Login

GOP-led Congress rejects Trump’s plans to gut medical research

Senate bill gives NIH a $400 million raise

YOU MAY BE INTERESTED IN

Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

HHS issues direct final rule to reduce reliance on animal testing

Cancer Grand Challenges, through the Torrey Coast Foundation and Cancer Research UK, commits up to $34M to gastroesophageal cancer research

The end of “more money, more people, more trials”Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Never miss an issue!

Login

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.